Merck Cuts 2025 Revenue Forecast, Pushes Ahead with US Expansion

The German pharmaceutical giant adjusts its guidance due to US tariffs and currency volatility but remains optimistic about growth, bolstered by a strategic acquisition of SpringWorks Therapeutics.